Labcorp reported a strong second quarter in 2026, with revenue rising 5.8% to $3.73 billion and adjusted EPS increasing 14.9% to $4.99, beating analyst expectations. The company attributed growth to steady demand for testing services and expansion in its drug-development business. Following these results, Labcorp raised its full-year guidance for both revenue and adjusted earnings, signaling confidence in continued positive momentum. Barclays also raised its price target for Labcorp to $320, indicating analyst optimism about the stock's potential.
UBS is close to completing its integration of Credit Suisse, marking a major strategic step. The bank reported strong Q2 results with net profit rising to $2.80 billion and revenues up 13.1% to $13.70 billion. Despite this, Morgan Stanley kept an Und...
Rentokil Initial PLC reported Q1 revenue of $3.59 billion, beating analyst expectations, but its earnings per share (EPS) of $0.39 fell short of the predicted $0.66. The company faces slowing growth in its key North American pest control market, with...
Dominion Energy, a diversified U.S. energy company, is gaining analyst confidence with its stock target price rising to $71, and some forecasts even higher. The company operates in regulated electricity, natural gas, and renewable energy, serving mil...
The District of Columbia Housing Finance Agency (DCHFA) has appointed Steve Clinton and Ed Fisher to its Board of Directors and reappointed Carri Robinson. Clinton brings over 40 years of housing finance expertise, including leadership roles at Fredd...
Agios Pharmaceuticals saw its stock surge after H.C. Wainwright raised the price target to $55, implying a 67% upside. The company reported Q2 2026 revenues of $44.75 million, nearly doubling estimates, driven by strong sales of its drug mitapivat (P...
